EGFR and neoplasm: Among the EGFR-TKI resistance signaling pathways, KRAS is an important signaling pathway downstream of EGFR, and the mutated KRAS gene directly activates the MAPK signaling pathway without relying on the activation of upstream EGFR, leading to tumor proliferation and metastasis (Wang et al., 2020).